TARS - Tarsus inks deal with LianBio for TP-03 development in Greater China

Tarsus Pharmaceuticals (TARS) and biotechnology company and LianBio announce a strategic partnership to develop and commercialize eye treatment TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau).TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and Meibomian Gland Disease ((MGD)), eye conditions with significant unmet treatment needs.As part of the deal, LianBio will obtain exclusive rights to develop and commercialize TP-03 in Greater China, and Tarsus will receive a $15M upfront payment, with further potential development and commercialization milestones of up to $185M.Tarsus will also be eligible to receive tiered low double-digit royalties based on sales of TP-03 in Greater China and will receive a minority equity stake in LianBio, which will vest upon the achievement of certain development and commercialization milestones.

For further details see:

Tarsus inks deal with LianBio for TP-03 development in Greater China